Corton Capital’s Arcturus Therapeutics ARCT Stock Holding History

Corton Capital’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13,338	Closed	-$174K	–	207
2025 Q2	$174K	Buy	+13,338	New	+$158K	0.2%	262
2023 Q3	–	Sell	-16,074	Closed	-$461K	–	425
2023 Q2	$461K	Sell	16,074 -3,255	-17%	-$88.6K	0.22%	117
2023 Q1	$463K	Buy	+19,329	New	+$347K	0.32%	75

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Corton Capital's ARCT Position: Q3 2025 in Review

Corton Capital sold out of Arcturus Therapeutics (ARCT) in Q3 2025, closing a stake of 13,338 shares — an estimated $174K sold.

Corton Capital first reported a position in ARCT in Q1 2023 and held it in 3 quarters. The position peaked at $463K in Q1 2023. 136 funds tracked by Wall St. Rank hold ARCT as of Q3 2025.

Corton Capital reported no remaining Arcturus Therapeutics position as of Q3 2025 after selling out during the quarter.
Corton Capital sold 13,338 Arcturus Therapeutics shares in Q3 2025, an estimated $174K.
Corton Capital first reported a position in Arcturus Therapeutics in Q1 2023 and held it in 3 quarters.
Corton Capital's Arcturus Therapeutics position peaked at $463K in Q1 2023.
136 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2025.

Based on Corton Capital's 13F filing for Q3 2025, filed 14 Nov 2025.